Esophageal cancer treatment in elderly patients: an inconvenient truth
Letter to the Editor

Esophageal cancer treatment in elderly patients: an inconvenient truth

Jeroen C. Hol, Joos Heisterkamp, Ingrid S. Martijnse, Robert A. Matthijsen, Barbara S. Langenhoff

Department of Surgery, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands

Correspondence to: Jeroen Clemens Hol. Department of Surgery, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands. Email: jeroenchol@gmail.com.

Response to: Yip HC, Chiu PW. Expanding indications of minimally invasive esophagectomy in elderly patients. Ann Esophagus 2019;2:9.
Kikuchi H, Takeuchi H. Minimally invasive esophagectomy in elderly patients: is it safe and feasible? Ann Esophagus 2019;2:7.
Peng JS, Hochwald SN. Minimally invasive esophagectomy in elderly patients. Ann Esophagus 2019;2:8.


Received: 14 July 2019; Accepted: 19 July 2019; Published: 19 August 2019.

doi: 10.21037/aoe.2019.07.01


We congratulate Yip, Kikuchi and Peng and their colleagues for providing their useful insights into the important topic of minimally invasive esophagectomy in elderly patients. Multiple studies show that esophageal cancer surgery in elderly patients is associated with high rates of postoperative morbidity and mortality (1,2). However, by focusing on postoperative outcomes, there is an inconvenient truth that has been concealed: the significance of the underlying disease that is often not reported in studies. Although steps have been made in the past decades to improve survival, the long-term outcome of locally advanced esophageal cancer remains poor (3). Surgical resection is the cornerstone of curative treatment. However, it is associated with significant morbidity and mortality. The question is: do we unnecessarily deprive patients of treatments that may improve survival? Second: can we select the best pathway for the individual patient?

One of the biggest issues is underrepresentation of elderly patients in clinical trials regarding esophageal cancer treatment. For example, elderly were not included in important trials investigating open versus minimally invasive surgery (4) and studies regarding the extent of lymphadenectomy (5). Moreover, elderly were not included in important studies on neoadjuvant therapy such as the CROSS trial (6). The CROSS trial demonstrated better survival after trimodality therapy with neoadjuvant chemoradiation, which is the golden standard these days in the Netherlands.

Relative contraindications for esophagectomy are comorbid illnesses, as they are associated with the risk of complications (7). The discussion of whether advanced age is a contraindication remains unsolved. Peng et al. mentioned the selection bias in retrospective studies and propose the use of a modified frailty index to predict morbidity and mortality after esophagectomy. We think such an objective measure is an important step in selecting patients and should be used in studies regarding improvement of postoperative outcomes (8). Furthermore, Peng et al. conclude that medically complex and elderly patients are best treated at experienced, high-volume centers. We would like to complement them on this statement and would like to add that centralization is a good first step in doing so (9).

There appears to be a bias in treatment choice in elderly patients with locally advanced cancer. Although elderly might benefit from more aggressive therapy including surgery, elderly with malignancies are more cautiously approached than their younger counterparts. The question is whether this is correct, as our study and other studies showed comparable morbidity and mortality after esophagectomy in both the elderly and younger groups after careful selection of the most appropriate treatment option per patient. Moreover, elderly might not only benefit from curative treatment: a near threefold improvement in median survival was seen in elderly receiving palliative treatment for esophageal cancer (10).

In conclusion, we think further research should focus on avoiding bias in selecting elderly for surgical treatment for esophageal cancer. After all, excluding elderly from curative treatment should be based on the right reasons. Therefore, care should be taken to avoid underrepresentation of elderly patients in research regarding esophageal cancer. It is of great importance, as this might be the way to reveal the truth regarding morbidity and mortality of elderly patients undergoing treatment for esophageal cancer.


Acknowledgments

None.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.


References

  1. Voncken FEM, van der Kaaij RT, Sikorska K, et al. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer. Am J Clin Oncol 2018;41:919-26. [Crossref] [PubMed]
  2. Hol JC, Heisterkamp J, Martijnse IS, et al. Morbidity and mortality in elderly patients after minimally invasive esophagectomy. Ann Esophagus 2019;2:3. [Crossref]
  3. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. [Crossref] [PubMed]
  4. Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012;379:1887-92. [Crossref] [PubMed]
  5. Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998;175:47-51. [Crossref] [PubMed]
  6. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84. [Crossref] [PubMed]
  7. Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 2005;55:231-40. [Crossref] [PubMed]
  8. POISE Study Group, Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839-47. [Crossref] [PubMed]
  9. Wouters MW, Karim-Kos HE, le Cessie S, et al. Centralization of esophageal cancer surgery: does it improve clinical outcome?. Ann Surg Oncol 2009;16:1789-98. [Crossref] [PubMed]
  10. Vlacich G, Samson PP, Perkins SM, et al. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database. Cancer Med 2017;6:2886-96. [Crossref] [PubMed]
doi: 10.21037/aoe.2019.07.01
Cite this article as: Hol JC, Heisterkamp J, Martijnse IS, Matthijsen RA, Langenhoff BS. Esophageal cancer treatment in elderly patients: an inconvenient truth. Ann Esophagus 2019;2:11.